Literature DB >> 8829124

Apolipoprotein E genotypes and risk of diabetic nephropathy.

T Onuma1, L M Laffel, M C Angelico, A S Krolewski.   

Abstract

Genetic susceptibility contributes to the development of diabetic nephropathy. In considering potentially important genetic factors, this study examined the association between genetic polymorphisms in apolipoprotein (apo) E and diabetic nephropathy in 146 patients with insulin-dependent diabetes mellitus (IDDM) of 15 to 21 years' duration. Using a case-control study design, patients with proteinuria (N = 41) (albumin excretion rate (AER) > or = 250 micrograms/min) and patients with microalbuminuria (N = 31) (AER 20 to 250 micrograms/min) were compared with patients who had normoalbuminuria (N = 74) (AER < 20 micrograms/min). Genetic polymorphisms at the apo E locus were identified by the method of denaturing gradient-gel electrophoresis. There was no significant difference in allele frequencies in the proteinuric, microalbuminuric, or normoalbuminuric groups (e2 7.3%, 9.7%, 9.5%; e3 78.1%, 72.6%, 68.2%; e4 14.6%, 17.7%, 22.3%; respectively). The distribution of the apo E genotypes among the three groups of patients was also similar. These results suggest that apo E genotypes are not associated with the development of early or advanced diabetic nephropathy in patients with IDDM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829124     DOI: 10.1681/ASN.V771075

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

1.  Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis.

Authors:  Yang Li; Kefu Tang; Zhao Zhang; Ming Zhang; Zhen Zeng; Zangdong He; Lin He; Chunling Wan
Journal:  Mol Biol Rep       Date:  2010-02-24       Impact factor: 2.316

Review 2.  Lipids and diabetic nephropathy.

Authors:  Rey F Rosario; Sharma Prabhakar
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

3.  Role of apolipoprotein E in renal damage protection.

Authors:  F Bonomini; L F Rodella; M Moghadasian; C Lonati; R Coleman; R Rezzani
Journal:  Histochem Cell Biol       Date:  2011-05-15       Impact factor: 4.304

Review 4.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

5.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

6.  Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome.

Authors:  Sung-Do Kim; Il-Soo Kim; Byung-Cheol Lee; Kang-Duk Choi; Joo-Ho Chung; Chun-Gyoo Ihm; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2003-02-13       Impact factor: 3.714

7.  Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.

Authors:  Anne Julie Overgaard; Tine E Thingholm; Martin R Larsen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Clin Proteomics       Date:  2010-09-10       Impact factor: 3.988

8.  The relationship of the apolipoprotein E gene polymorphism Turkish Type 2 diabetic patients with and without nephropathy.

Authors:  M Erdogan; Z Eroglu; C Biray; M Karadeniz; S Cetinkalp; B Kosova; C Gunduz; N Topcuoglu; G Ozgen; C Yilmaz
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

9.  Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study.

Authors:  N S Shcherbak
Journal:  BMC Med Genet       Date:  2001-07-24       Impact factor: 2.103

10.  Apolipoprotein E and kidney function in older adults.

Authors:  Rebecca Kurnik Seshasai; Ronit Katz; Ian H de Boer; David Siscovick; Michael G Shlipak; Dena E Rifkin; Mark J Sarnak
Journal:  Clin Nephrol       Date:  2012-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.